Sunday 18 October 2026
Export DHAI’s income statement to Excel — free account
DIH Holding US, Inc.
DHAI Healthcare Medical Devices
DIH Holding US, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $62.9 million, down 2.50% from fiscal 2024. In the quarter to March 2025, revenue fell 30.7%, EPS grew 30.0% and free cash flow fell 167.9%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow DHAI
| Mar '25 | Dec '24 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.01 | 0.69 | 0.98 | 1.52 | |
P/FCF ratio |
0.00 | 12.93 | 23.71 | 19.91 | |
P/Operating CF |
(0.10) | 69.69 | 137.89 | (46.58) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.15 | 0.84 | 1.14 | 1.69 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.28) | 13.34 | 21.99 | 19.99 | |
EV/FCF |
(2.02) | 15.67 | 27.42 | 22.16 | |
Quick Ratio |
0.20 | 0.24 | 0.30 | 0.29 | |
Current Ratio |
0.49 | 0.51 | 0.60 | 0.61 | |
Net Debt/EBITDA |
(2.13) | (4.08) | 4.78 | (6.79) | |
Debt/Assets |
41.33% | 35.39% | 32.26% | 34.97% | |
Debt/Equity |
(0.30) | (0.30) | (0.36) | (0.39) | |
Asset Turnover |
2.01 | 1.54 | 1.36 | 0.51 | |
Operating CF/Net income |
0.80 | (0.18) | (2.03) | 3.27 | |
Capex/Depreciation |
(0.40) | (0.08) | (0.72) | (2.58) | |
Interest Coverage |
(16.96) | (109.84) | 72.62 | — | |
Research and Development Expense of Revenue |
13.08% | 11.83% | 10.52% | 10.16% | |
Selling, General and Administrative Expense of Revenue |
54.78% | 54.30% | 31.70% | 53.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 2.98% | 0.00% | 0.00% | |
Graham Net Nets |
(129.22) | (0.95) | (0.65) | (0.46) | |
Graham Number |
301.41 | 67.55 | 63.30 | 74.02 | |
Earnings Yield |
(107.60%) | (21.51%) | (15.06%) | (14.61%) | |
Free Cash Flow Yield |
(1,415.54%) | 7.73% | 4.22% | 5.02% | |
Revenue per Share |
234.63 | 10.89 | 13.14 | 11.71 | |
Operating CF per Share |
(57.62) | 0.50 | 0.34 | (1.45) | |
Capex per Share |
(1.61) | (0.02) | (0.14) | (0.17) | |
Free Cash Flow per Share |
(59.23) | 0.48 | 0.21 | (1.62) | |
Cash per Share |
33.90 | 0.81 | 1.49 | 1.99 | |
Shareholders Equity per Share |
(649.21) | (27.34) | (24.89) | (24.60) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(649.21) | (27.34) | (24.89) | (24.60) | |
Free Cash Flow |
(3.39) | 0.67 | 0.29 | (2.24) | |
Working Capital |
(21.69) | (23.17) | (19.59) | (18.86) | |
Capital Expenditures |
(0.09) | (0.02) | (0.19) | (0.23) | |
Net Current Asset Value |
(42.72) | (45.54) | (42.81) | (42.83) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.80 | — | — | — | |
Average Payables |
3.83 | 3.15 | 3.61 | 2.90 | |
Average Inventory |
7.44 | — | — | — | |
Average Assets |
31.24 | 44.68 | 49.24 | 122.04 | |
Average Common Equity |
(34.84) | (24.91) | (22.75) | (22.23) |
Columns are period end dates · fundamentals updated 28 Sep 2026